SpaceX to launch new Intuitive Machines moon lander, lunar satellites in 2027
When you buy through links on our articles, Future and its syndication partners may earn a commission.
Intuitive Machines may have crashed its latest moon lander on the lunar surface, but that's not keeping the company down for long.
The Houston-based company has picked SpaceX to launch IM-4, its fourth moon lander, on a Falcon 9 rocket in 2027 alongside two relay satellites for a NASA lunar communications network. The news comes just weeks after the company's IM-2 moon lander crashed near the moon's south pole, and as the firm continues work on its third moon lander (yes, it's called IM-3), which is expected to launch in 2026.
'Lunar surface delivery and data relay satellites are central to our strategy to commercialize the Moon," Intuitive Machines CEO Steve Altemus said in a statement Tuesday (April 8). "We plan to deploy the first of five lunar data relay satellites on our third mission, which will introduce our pay-by-the-minute service. The two additional satellites on our fourth mission are intended to scale that service, followed by two additional deployments to complete the constellation and fully support NASA and commercial lunar operations." The relay satellites will support NASA's Near Space Network Services contract, Intuitive Machines wrote.
Intuitive Machines' IM-4 moon lander will carry six NASA payloads under a contract with the agency's Commercial Lunar Payload Services program. A new drill experiment built by the European Space Agency to hunt for water near the moon's south pole, will be aboard.
Intuitive Machines' first moon lander, called IM-1 Odysseus, tipped over after breaking a landing leg while attempting to land in 2024. The second lander, the IM-2 Athena, fell on its side during a lunar south pole landing attempt on March 6.
The IM-3 moon lander is under construction now.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
China robotaxis, Indian pharma among hedge fund top picks at Sohn Hong Kong
By Summer Zhen HONG KONG (Reuters) -Hedge funds revealed their top investment ideas, ranging from Chinese self-driving taxis, an Indian drug retailer, to a Korean nuclear plant builder, at the annual Sohn investment conference in Hong Kong. This year's picks are geographically more diverse compared to last year, suggesting that investors are actively seeking to spread their exposure to counter tariff uncertainties and market volatility. San Francisco-based Flight Deck Capital sees upside potential in Chinese search engine giant Baidu, betting on its fast-growing auto-driving business. Similar to Google's self-driving unit Waymo, Baidu's Apollo Go "is the only robo-taxi player in China that's not dependent on the capital markets to scale," Flight Deck founder and managing partner Jay Kahn said at the conference on Friday. He expects China's taxi and ride-share industry to grow to around $237 billion by 2034, with Apollo taking a 15% market share. But that segment, together with Baidu's cloud business, is currently given zero valuation by the market, he said. Notably, investor optimism on Chinese firms going overseas has not been derailed by the escalating U.S.-China trade war. Hong Kong's Apeiron Capital pitched Chinese ride-hailing company DiDi Global, citing its improving margin at home and its quick market share building in Latin America. Meanwhile Triata Capital is upbeat on Chinese discount e-commerce player PDD, the owner of Temu. "One statistic that a lot of people don't know is that their MAU right now is bigger than Amazon," Triata CIO Sean Ho said, referring to Temu's monthly active users. INDIA Two investors set their sights on India's healthcare space. Singapore's Arisaig Partners favors MedPlus Health Services, a leading pharmacy chain in India, as its private label products strengthen its low-price proposition, widening the gap with competitors. "Inflation is lower, government is focusing on the middle class and consumer spending is coming off a low base. I simply believe this is the time when the consumer space in general will do better," Vatsal Mody, partner and head of India research at Arisaig Partners said in an interview ahead of the conference. India-based hedge fund startup Panvira Management is bullish on Piramal Pharma, a contract development and manufacturing organisation (CDMO), expecting its growth to accelerate to high teens and to benefit from tax rate normalisation. SECURITY AND ACTIVISTS Other emerging hedge funds focused on opportunities in the security sector driven by geopolitical conflicts. Jon Jhun, who manages Management's new Korea-focused fund, chose Hyundai Engineering & Construction, which engages in nuclear plant engineering, procurement and construction (EPC). "Korea dominates the ex-Russia, ex-China nuclear supply chain," he said. Hong Kong's Frontline Global Management picked Spanish defence firm Indra Sistemas, believing the firm will win more European contracts. On the activist investor side, UK hedge fund Palliser Capital disclosed a 3% stake in Japan's Toyo Tire at the event, urging the tire maker to boost shareholder returns by setting a "best-in-class" performance target and releasing its excess capital of about $900 million to shareholders. Seth Fischer's Oasis Management is long Japanese entertainment complex chain Round One, betting it will gain a re-rating as it ventures into the restaurant industry aiming to bring Michelin-quality Japanese food to the U.S. Sign in to access your portfolio
Business Insider
22 minutes ago
- Business Insider
Novocure announces results from Phase 3 PANOVA-3 trial
Novocure (NVCR) announced that results from the Phase 3 PANOVA-3 trial of Tumor Treating Fields therapy for pancreatic cancer will be presented at the 2025 American Society of Clinical Oncology, ASCO, Annual Meeting in Chicago and simultaneously published in the Journal of Clinical Oncology. The trial met its primary endpoint, demonstrating a statistically significant improvement in median overall survival for patients treated with TTFields. TTFields therapy concomitant with gemcitabine and nab-paclitaxel demonstrated improvement in several secondary endpoints including the one-year survival rate and pain-free survival. The one-year survival rate showed a statistically significant improvement in the TTFields concomitant with gemcitabine and nab-paclitaxel treated group with compared to those who received gemcitabine and nab-paclitaxel alone. Patients treated with TTFields concomitant with gemcitabine and nab-paclitaxel had a median pain-free survival of 15.2 months compared to a median 9.1 months in the group treated with gemcitabine and nab-paclitaxel alone. This is a statistically significant 6.1-month extension in pain-free survival. Pain-free survival was defined as the time from baseline until an increase of 20 or more points was reported by patients on a visual scale for pain or until death.
Business Insider
22 minutes ago
- Business Insider
AstraZeneca announces results from MATTERHORN Phase III trial of IMFINZI
Positive results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca's (AZN) IMFINZI in combination with standard-of-care FLOT chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival, EFS, versus chemotherapy alone. Patients were treated with neoadjuvant IMFINZI in combination with chemotherapy before surgery, followed by adjuvant IMFINZI in combination with chemotherapy, then IMFINZI monotherapy. The trial evaluated this regimen versus perioperative chemotherapy alone for patients with resectable, early-stage and locally advanced gastric and gastroesophageal junction, GEJ, cancers. In a planned interim analysis, patients treated with the IMFINZI-based perioperative regimen showed a 29% reduction in the risk of disease progression, recurrence or death versus chemotherapy alone. Estimated median EFS was not yet reached for the IMFINZI arm versus 32.8 months for the comparator arm. For the secondary endpoint of overall survival, a strong trend was observed in favor of the IMFINZI-based perioperative regimen. The trial will continue to follow OS, which will be formally assessed at the final analysis. Confident Investing Starts Here:
